Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
P54315
UPID:
LIPR1_HUMAN
Alternative names:
-
Alternative UPACC:
P54315; Q68D83; Q68DR6; Q8TAU2; Q9BS82
Background:
Inactive pancreatic lipase-related protein 1, as its name suggests, may play a role in inhibiting the digestion of dietary triglycerides. Despite its classification, it does not exhibit lipase activity towards triglycerides or other lipid substrates in vitro, suggesting a unique function in lipid metabolism.
Therapeutic significance:
Understanding the role of Inactive pancreatic lipase-related protein 1 could open doors to potential therapeutic strategies. Its unique function in lipid metabolism makes it a subject of interest for developing novel approaches to managing dietary fat absorption and related metabolic disorders.